Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
FDIC chairman Martin Gruenberg to step down, White House says
Street Known for Good Family Values, Traditions
Organizations Work Together to Protect Women, Children's Rights, Interests
Lucheng Women's Federation Promotes Law
Inner Mongolia Strengthens Protection of Women's Rights, Interests
2022 'She Can' Public Welfare Project Kicks off in Chengdu
Helping, Caring for Juvenile Offenders
Ravens sign WR Qadir Ismail, the son of former NFL receiver Qadry Ismail
2022 'She Can' Public Welfare Project Kicks off in Chengdu
Cannes 2024: Studio Ghibli takes a bow with an honorary Palme d'Or
Micro Courts Provide Legal Services to Women